Boehringer, Lupin to co-market diabetes drug

Mumbai: MNC drug firm Boehringer Ingelheim and domestic company Lupin announced an alliance to co-market anti-diabetes drug, Empagliflozin, a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor in India. This is the second partnership between the two in the diabetes space. SGLT-2 Inhibitors are a novel class of drugs that were launched across the world in the last couple of years.According to the agreement, Lupin will market and sell Empagliflozin under a separate brand name Gibtulio, which will be promoted by Lupin’s specialty field force.
Boehringer Ingelheim will continue to sell Empagliflozin under the brand name Jardiance through their existing sales force and network.
Earlier, the companies had earlier signed a partnership for co-marketing diabetes drug, linagliptin in October last year.